ViroPharma's Cinryze granted European approval for hereditary HAE
This article was originally published in Scrip
Executive Summary
The European Commission has approved ViroPharma's C1 Inhibitor, Cinryze, for use in adults and adolescents with hereditary angioedema (HAE).